What Is Galleri Test

The Galleri test is a blood-based multi-cancer early detection (MCED) test developed by GRAIL that screens for shared signals across more than 50 cancer types. It works by analyzing methylation patterns on cell-free DNA (cfDNA) fragments shed by tumors into the bloodstream. A single blood draw provides both a cancer signal status and a predicted tissue of origin if a signal is detected.

Most cancers are discovered only after symptoms appear, often at advanced stages when treatment options narrow and outcomes worsen. Standard screening protocols cover a limited number of cancers: breast, cervical, colorectal, lung, and prostate account for the majority of guideline-recommended screens. The remaining cancer types, many of them lethal, have no routine early detection method. A test capable of flagging dozens of cancer types from a single blood sample addresses a significant gap in preventive medicine.

From a longevity perspective, cancer remains one of the leading causes of death and disability worldwide. Detecting malignancies at earlier stages is associated with higher survival rates across nearly all cancer types. A screening tool that identifies cancers for which no other screening exists could, in principle, shift diagnosis toward earlier, more treatable stages, directly influencing healthspan and lifespan. The degree to which the Galleri test achieves this at a population level is still under investigation in large prospective trials.

When cells die, they release fragments of their DNA into the bloodstream. These cell-free DNA fragments carry chemical modifications called methylation marks, which act as molecular signatures specific to the tissue of origin and its disease state. Cancer cells exhibit abnormal methylation patterns that differ markedly from those of healthy cells. The Galleri test captures these cfDNA fragments from a standard blood sample and performs targeted methylation sequencing on over 100,000 informative methylation regions across the genome.

A machine learning classifier trained on thousands of cancer and non-cancer samples reads the methylation data and assigns a binary result: "signal detected" or "signal not detected." When a signal is detected, the algorithm also predicts the cancer signal origin (CSO), identifying where in the body the cancer is most likely located. This prediction helps direct subsequent diagnostic workup toward the relevant organ or tissue, reducing the need for broad, unfocused imaging.

The test does not analyze tumor mutations or structural DNA changes, which distinguishes it from other liquid biopsy approaches. By focusing on methylation, the test leverages a cancer hallmark that is broadly shared across tumor types rather than relying on type-specific genetic alterations. This methylation-based approach is what enables the test to screen across such a wide range of cancers in a single assay.

The Galleri test measures methylation patterns on cell-free DNA fragments circulating in the bloodstream. Methylation is a chemical modification where methyl groups attach to specific locations on DNA, regulating gene expression. In cancer, these methylation patterns become distinctively altered, and when tumor cells die and release their DNA into the blood, these abnormal patterns become detectable.

The test performs targeted bisulfite sequencing across more than 100,000 methylation sites. A trained classifier analyzes the aggregate methylation signal to determine whether cancer-associated patterns are present. If a cancer signal is detected, the classifier also predicts the cancer signal origin, identifying the most likely anatomic site. The test does not measure tumor mutations, protein biomarkers, or circulating tumor cells, which distinguishes it from other forms of liquid biopsy.

Preparation for the Galleri test is minimal. The test requires a standard venous blood draw, and no fasting is required. There are no dietary, medication, or activity restrictions before the test. The blood sample is collected in specialized collection tubes and shipped to a central laboratory for processing.

The test must be ordered by a licensed healthcare provider. Some direct-to-consumer pathways exist through telehealth platforms, but a clinician order is still required. Before testing, it is worth confirming that all standard age-appropriate and risk-appropriate cancer screenings are up to date, as the Galleri test is intended as a complement to, not a substitute for, those established protocols.

Results are returned in approximately two weeks and fall into one of two categories: "cancer signal not detected" or "cancer signal detected." A "not detected" result means the classifier did not identify methylation patterns consistent with cancer in the sample. This does not guarantee cancer is absent; the test's sensitivity is limited, especially for stage I tumors and certain cancer types. Continued participation in standard screening remains important.

A "signal detected" result includes a cancer signal origin (CSO), which indicates the tissue or organ most likely to harbor the malignancy. This result is not a cancer diagnosis. It is a screening signal that requires confirmatory diagnostic workup, typically guided by the CSO prediction. Diagnostic steps may include imaging (CT, MRI, PET), endoscopy, or biopsy, depending on the predicted origin. In a small percentage of cases, follow-up workup may not identify a confirmed cancer, reflecting the test's false positive rate. A clinician experienced with MCED results can help navigate next steps and manage the uncertainty inherent in any screening process.

The manufacturer recommends annual testing for eligible individuals. Because cancer is a dynamic process and the amount of cfDNA shed varies with tumor size and biology, a cancer that is undetectable in one year may become detectable in the next as it grows and releases more DNA. Serial annual testing therefore increases the cumulative probability of catching a cancer during a window when intervention may still be effective.

There is no established evidence base defining the optimal testing interval. Annual cadence aligns with the approach used in the NHS-Galleri trial and other clinical studies. For individuals with significant risk factors, such as strong family history or known genetic predispositions, the decision about frequency and timing should be individualized with a clinician who understands both the test's capabilities and its limitations.

The Galleri test has been evaluated in several clinical studies. The Circulating Cell-free Genome Atlas (CCGA) study, a large case-control study, provided foundational data on the test's sensitivity and specificity. Across all cancer types and stages, overall sensitivity was reported near 50%, with specificity exceeding 99%. Sensitivity was substantially higher for later-stage cancers (stages III and IV) and lower for stage I disease, which is a recognized limitation. The cancer signal origin prediction was accurate in roughly 90% of cases where a signal was detected.

The NHS-Galleri trial, a large randomized controlled trial conducted within the United Kingdom's National Health Service, is the most significant prospective evaluation. Early results indicated that the test detected cancers across a broad range of types, with a higher proportion found at earlier stages compared to the control arm, though the magnitude of stage-shift benefit and its effect on mortality are still being assessed. Additional real-world evidence studies and a planned pivotal trial for regulatory submission are underway. The test is currently available as a laboratory-developed test (LDT) in the United States and has not yet received FDA approval or premarket clearance. Long-term data on whether routine use of the Galleri test reduces cancer mortality are not yet available.

False positives, though infrequent given the high specificity, can trigger anxiety and lead to invasive follow-up procedures, including imaging and biopsies, that may carry their own risks. False negatives are more common, particularly for early-stage cancers, and a "no signal detected" result should not be interpreted as a clean bill of health. The test does not replace standard cancer screening. Overdiagnosis, the detection of cancers that would never have caused symptoms or death, is a theoretical concern with any broad screening approach, though the clinical significance of this for the Galleri test is not yet well characterized. The out-of-pocket cost, typically several hundred dollars, may be a barrier, and insurance coverage remains limited. Individuals should interpret results with the guidance of a qualified clinician who can contextualize findings within a broader health picture.